Q-omics provides the consensus-scored PSMD3 profile across patient tissues and cancer cell-line models. PSMD3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PSMD3 is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, PSMD3 protein abundance shows 23,001 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where PSMD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMD3 survival associations across molecular data types. PSMD3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMD3 RNA expression–survival associations across cancer types. High PSMD3 expression shows unfavorable associations in KIRP, MESO, UVM, LIHC, ACC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PSMD3 RNA expression.
This table summarizes PSMD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMD3 shows higher tumor expression in HNSC, KIRC, BLCA, COAD, KIRP and LUAD. The HNSC box plot shows higher PSMD3 RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with PSMD3 in patient tissues and cancer cell lines. In patient samples, PSMD3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and URINARY_TRACT.
